STOCK TITAN
  1. Home
  2. Sec-filings
  3. IMNN
  4. [Form 4] Imunon, Inc. Insider Trading Activity

Imunon (IMNN) chair takes half of 2025 cash bonus in stock grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Tardugno Michael H reported acquisition or exercise transactions in this Form 4 filing.

Imunon, Inc. Executive Chairman Michael H. Tardugno received a stock grant as part of his 2025 compensation. He was awarded 42,519 shares of common stock at $1.72 per share, granted in lieu of cash for 50% of his 2025 annual cash bonus.

Following this grant, Tardugno holds 59,986 shares of Imunon common stock directly, plus 4,622 shares held indirectly through an IRA. The filing shows a compensation-related share award rather than an open-market purchase or sale.

Positive

  • None.

Negative

  • None.
Insider Tardugno Michael H
Role Executive Chairman of Board
Type Security Shares Price Value
Grant/Award Common Stock 42,519 $1.72 $73K
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 59,986 shares (Direct, null); Common Stock — 4,622 shares (Indirect, Held by IRA)
Footnotes (1)
  1. [object Object]
Stock grant shares 42,519 shares Common stock grant in lieu of 50% of 2025 annual cash bonus
Grant price $1.72 per share Value per share used for the 42,519-share stock grant
Direct holdings after grant 59,986 shares Common stock directly owned by Michael H. Tardugno after the grant
Indirect IRA holdings 4,622 shares Common stock held indirectly through an IRA after the reported entry
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
Held by IRA financial
"nature_of_ownership: Held by IRA"
annual cash bonus financial
"Stock granted in lieu of cash for 50% of 2025 annual cash bonus"
Form 4 regulatory
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Tardugno Michael H
(Last)(First)(Middle)
C/O IMUNON, INC.
997 LENOX DRIVE, SUITE 100
(Street)
LAWRENCEVILLE NEW JERSEY 08648
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Executive Chairman of Board
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/25/2026A42,519(1)A$1.7259,986D
Common Stock4,622IHeld by IRA
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Stock granted in lieu of cash for 50% of 2025 annual cash bonus
/s/ Susan Eylward, Attorney-in-Fact for Michael Tardugno06/29/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Imunon (IMNN) report for Michael H. Tardugno?

Imunon reported a compensation-related stock grant to Executive Chairman Michael H. Tardugno. He received 42,519 common shares at $1.72 per share, granted instead of cash for half of his 2025 annual cash bonus, increasing his direct holdings to 59,986 shares.

Was the Imunon (IMNN) Form 4 transaction a market buy or sell?

The Form 4 reports a grant or award, not a market trade. Tardugno received 42,519 Imunon common shares at $1.72 per share as compensation in lieu of 50% of his 2025 cash bonus, rather than buying or selling shares on the open market.

How many Imunon (IMNN) shares does Michael H. Tardugno hold after this grant?

After the grant, Tardugno holds 59,986 Imunon common shares directly and 4,622 shares indirectly through an IRA. The Form 4 shows the 42,519-share award increased his direct ownership to this level, with the IRA position reported separately as indirect ownership.

What is the value basis of the Imunon (IMNN) stock grant to the executive chairman?

The stock grant to Tardugno is recorded at $1.72 per share for 42,519 shares of Imunon common stock. This per-share value is used in the filing to describe the grant, which replaces cash for 50% of his 2025 annual bonus rather than providing additional cash compensation.

How is Michael H. Tardugno’s 2025 bonus structured at Imunon (IMNN)?

According to the Form 4 footnote, 50% of Tardugno’s 2025 annual cash bonus is being paid in stock. He received 42,519 Imunon common shares at $1.72 per share in lieu of that portion of the bonus, aligning part of his compensation with equity instead of cash.